Synthesis and biological evaluation of chromone derivatives against triple-negative breast cancer cells

被引:2
|
作者
Islam, Rajibul [1 ]
Yan, Mock Phooi [1 ]
Yen, Khor Poh [2 ]
Rasol, Nurulfazlina Edayah [3 ,4 ]
Meng, Chan Kok [5 ]
Wai, Lam Kok [1 ]
机构
[1] Univ Kebangsaan Malaysia, Fac Pharm, Ctr Drug & Herbal Dev, Kuala Lumpur 50300, Malaysia
[2] Univ Kuala Lumpur, Royal Coll Med Perak, Fac Pharm & Hlth Sci, Ipoh 30450, Perak, Malaysia
[3] Univ Teknol MARA, Atta ur Rahman Inst Nat Prod Discovery, Puncak Alam Campus, Bandar Puncak Alam 42300, Selangor, Malaysia
[4] Univ Teknol MARA, Fac Appl Sci, Shah Alam 40450, Selangor, Malaysia
[5] Univ Kebangsaan Malaysia, Fac Hlth Sci, Ctr Toxicol & Hlth Risk Studies, Jalan Raja MudaAbdul Aziz, Kuala Lumpur 50300, Malaysia
关键词
Triple-negative breast cancer; Chromone; Anticancer; Multi-kinase inhibitor; INHIBITOR LY294002; KINASE; DOXORUBICIN; DESIGN; DEATH; PROLIFERATION; OPTIMIZATION; CHEMOTHERAPY; EXPRESSION; EFFICIENT;
D O I
10.1007/s00044-023-03048-4
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This study described the bioactivity and the structure-activity relationship (SAR) of newly synthesized chromone derivatives against triple-negative breast cancer (TNBC) MDA-MB-231 cells. Among the compounds tested, C8 exerted a growth inhibitory effect on the TNBC-derived MDA-MB-231 cells with an IC50 value of 11.71 +/- 0.79 mu M. Results showed that it could promote apoptosis, sensitize TNBC MDA-MB-231 cells to doxorubicin (Dox) and inhibit multiple kinase activities with higher selectivity against PIM1 and PIM2 kinases. Molecular docking results revealed compound C8 engaged in several critical interactions with the important residues in PIM1 and PIM2 binding sites. This suggests that compound C8 possessed anticancer activity on TNBC cells potentially mediated by inhibition of multiple tyrosine kinases and kinases involved in cell-cycle regulation.
引用
收藏
页码:884 / 898
页数:15
相关论文
共 50 条
  • [41] Unlocking the effective alliance of β-lapachone and hydroxytyrosol against triple-negative breast cancer cells
    Calahorra, Jesus
    Blaya-Canovas, Jose L.
    Castellini-Perez, Olivia
    Aparicio-Puerta, Ernesto
    Cives-Losada, Candela
    Marin, Jose J. G.
    Rementeria, Markel
    Cara, Francisca E.
    Lopez-Tejada, Araceli
    Grinan-Lison, Carmen
    Aulicino, Francesco
    Berger, Imre
    Marchal, Juan A.
    Delgado-Almenta, Violeta
    Granados-Principal, Sergio
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 174
  • [42] Synergistic effects of epoxyazadiradione (EAD) and paclitaxel against triple-negative breast cancer cells
    Sijisha, Kunnathully Sudhan
    Anusha, Rajitha
    Priya, Sulochana
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2024, 38 (04) : 758 - 766
  • [43] Triple-Negative Breast Cancer: Not Entirely Negative
    Leone, Jose Pablo
    Puhalla, Shannon
    ONCOLOGY-NEW YORK, 2013, 27 (09): : 856 - +
  • [44] Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer
    Niedolistek, Magdalena
    Fudalej, Marta M.
    Sobiborowicz, Aleksandra
    Liszcz, Anna
    Budzik, Michal P.
    Sobieraj, Maciej
    Patera, Janusz
    Czerw, Aleksandra
    Religioni, Urszula
    Sobol, Maria
    Deptala, Andrzej
    Badowska-Kozakiewicz, Anna M.
    ARCHIVES OF MEDICAL SCIENCE, 2024, 20 (02) : 436 - 443
  • [45] Theranostics for Triple-Negative Breast Cancer
    Choi, Hyeryeon
    Kim, Kwangsoon
    DIAGNOSTICS, 2023, 13 (02)
  • [46] Advanced Triple-Negative Breast Cancer
    Patel, Grisma
    Prince, Alison
    Harries, Mark
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
  • [47] What is triple-negative breast cancer?
    Irvin, William J., Jr.
    Carey, Lisa A.
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (18) : 2799 - 2805
  • [48] Immunotherapy in Triple-Negative Breast Cancer
    Emens, Leisha A.
    CANCER JOURNAL, 2021, 27 (01): : 59 - 66
  • [49] Pembrolizumab in Triple-Negative Breast Cancer
    Altundag, Kadri
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (15): : 1435 - 1436
  • [50] A Review of Triple-Negative Breast Cancer
    Ismail-Khan, Roohi
    Bui, Marilyn M.
    CANCER CONTROL, 2010, 17 (03) : 173 - 176